SCHEMBL4546381

SCHEMBL4546381

CC(C)c1nnsc1C(C)C

nearest known ligand 0.34

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.34
SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18611000 0.72
SCHEMBL9608969 0.69 SLC6A2 (0.45) SLC6A2SLC6A3
SCHEMBL17824655 0.67 SLC6A2 (0.44) SLC6A2SLC6A3
SCHEMBL20209762 0.60
SCHEMBL18648682 0.60
SCHEMBL16233615 0.60
SCHEMBL20079870 0.59
SCHEMBL10063452 0.56
SCHEMBL12922239 0.55 ALDH1A1 (0.31)
SCHEMBL18999978 0.52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 US disclosed
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-11-09 US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 US disclosed
US-11702422-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-18 US disclosed
US-11691979-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
US-11691979-B2 Imidazopyridazines as modulators of IL-17 JANSSEN PHARMACEUTICA NV (BE) 2023-07-04 US disclosed
US-20230110495-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2023-04-13 US disclosed
US-20220402922-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 JANSSEN RESEARCH & DEVELOPMENT, LLC 2022-12-22 US disclosed
US-20220235032-A1 BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2022-07-28 US disclosed
US-20210052586-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES OXALURX, INC. 2021-02-25 US disclosed
US-20090264423-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-10-22 US disclosed
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS SENHWA BIOSCIENCES, INC. (TW) 2009-04-23 US disclosed
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS CYLENE PHARMACEUTICALS, INC. (US) 2009-04-09 US disclosed
US-20090082565-A1 METHODS OF PREPARING QUINOLONE ANALOGS CYLENE PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed
US-20090082565-A1 METHODS OF PREPARING QUINOLONE ANALOGS CYLENE PHARMACEUTICALS, INC. (US) 2009-03-26 US disclosed
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS GRUNENTHAL GMBH (DE) 2009-03-19 US disclosed
US-20080318939-A1 METHODS FOR TREATING OPHTHALMIC DISORDERS CYLENE PHARMACEUTICALS, INC. 2008-12-25 US disclosed
US-20080318938-A1 METHODS FOR TREATING ABERRANT CELL PROLIFERATION DISORDERS CYLENE PHARMACEUTICALS, INC. 2008-12-25 US disclosed
US-7402606-B2 Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin K inhibitors for the treatment of bone loss SMITHKLINE BEECHAM CORPORATION (US) 2008-07-22 US disclosed
US-20070032652-A1 Methods of preparing quinolone analogs SENHWA BIOSCIENCES, INC. (TW) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318939-A1 METHODS FOR TREATING OPHTHALMIC DISORDERS EYA3, UACA, ALDH1A2 SLC6A2 2754/4885SLC6A3 3004/4885
US-11691979-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 SLC6A2 3987/4885SLC6A3 3427/4885
US-20230357254-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 SLC6A2 3987/4885SLC6A3 3427/4885
US-20090082565-A1 METHODS OF PREPARING QUINOLONE ANALOGS BAX, BAD, MCL1 SLC6A2 3755/4885SLC6A3 3483/4885
US-20220402922-A1 IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 IL17A, IL23R, IL15 SLC6A2 3987/4885SLC6A3 3427/4885
US-20210052586-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT SLC6A2 1769/4885SLC6A3 1450/4885
US-11702422-B2 Imidazopyridazines as modulators of IL-17 IL17A, IL23R, IL15 SLC6A2 3987/4885SLC6A3 3427/4885
US-20080318938-A1 METHODS FOR TREATING ABERRANT CELL PROLIFERATION DISORDERS MKI67, PCNA, CCNC SLC6A2 3372/4885SLC6A3 3430/4885
US-20230110495-A1 COMPOUNDS AND METHODS FOR TREATING OXALATE-RELATED DISEASES XDH, PNPO, OAT SLC6A2 1769/4885SLC6A3 1450/4885
US-20090093465-A1 THERAPEUTIC KINASE MODULATORS PACSIN2, CKS1B, CSNK1A1 SLC6A2 4741/4885SLC6A3 4755/4885
US-20090264423-A2 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 SLC6A2 4728/4885SLC6A3 4671/4885
US-20090075978-A1 SUBSTITUTED PROPIOLIC ACID AMIDES AND THEIR USE FOR PRODUCING DRUGS PCCA, PPARA, PTGES SLC6A2 1151/4885SLC6A3 1402/4885
US-20220235032-A1 BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF RIPK1, RIPK4, RIPK3 SLC6A2 4755/4885SLC6A3 3668/4885
US-20090105233-A1 SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS PACSIN2, TNKS, PARP1 SLC6A2 4728/4885SLC6A3 4671/4885
US-20070032652-A1 Methods of preparing quinolone analogs BAX, BAD, MCL1 SLC6A2 3755/4885SLC6A3 3483/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.